Breaking News

Financial Report: Biogen

January 27, 2016

TECFIDERA drives revenues in 2015

Biogen

4Q Revenues: $2.8 billion (+8%)

4Q Earnings: $828.7 million (-6%)

FY Revenues: $10.8 billion (+11%)

FY Earnings: $3.5 billion (+21%)

Comments: TECFIDERA revenues were $3.6 billion for the year, up 24%, with $2.9 billion in U.S. sales and $730 million in sales outside the U.S. Interferon revenues, including AVONEX and PLEGRIDY, were $3.0 billion, down 3%, with $2.0 billion in U.S. sales and $951 million in sales outside the U.S. TYSABRIrevenues were $1.9 billion, down 5%, with $1.1 billion in U.S. sales and $783 million in sales outside the U.S. Revenues relating to RITUXAN and GAZYVA from Biogen’s unconsolidated joint business arrangement were $1.3 billion, up 8%. Royalty revenues were $48 million compared to $177 million in 2014.
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments